Pharmacology Research & Perspectives

Papers
(The H4-Index of Pharmacology Research & Perspectives is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Diversity of molecular targets and signaling pathways for CBD144
Molnupiravir: A new candidate for COVID‐19 treatment82
Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: A randomized, double‐blind, controlled trial80
“LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy74
Drug discovery: Insights from the invertebrate Caenorhabditis elegans57
The antimicrobial effect behind Cannabis sativa45
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent38
Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature37
Inter‐ethnic differences in pharmacokinetics—is there more that unites than divides?36
Strategies to apply 3Rs in preclinical testing36
Histamine in cancer immunology and immunotherapy. Current status and new perspectives33
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology31
Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract30
Spermidine and spermine exert protective effects within the lung29
An overview of diagnosis and management of drug‐induced hypomagnesemia29
The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: A randomized controlled trial28
The interacting physiology of COVID‐19 and the renin‐angiotensin‐aldosterone system: Key agents for treatment28
Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview28
Identification of the metabolites of ivermectin in humans26
Pros and cons for statins use and risk of Parkinson's disease: An updated perspective26
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 825
Alleviation of cisplatin‐induced hepatotoxicity by gliclazide: Involvement of oxidative stress and caspase‐3 activity24
Gut microbiota disorder caused by diterpenoids extracted from Euphorbia pekinensis aggravates intestinal mucosal damage24
Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor23
CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression23
0.10032892227173